All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Nikhil MunshiDuring the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, about chimeric antigen receptor (CAR) T-cell therapy for MM.
How can we predict responses to CAR T-cell therapies, such as bb2121?
CAR T cells have proven to be an extremely effective therapy, with 73–100% of patients responding to treatment. In recent studies, complete response (CR) rates of 33–86% have been achieved. So the question becomes, can we predict which patients will achieve CR?
While there is no clear method, there is some evidence linking expansion of T cells and response to therapy. In this video, Nikhil Munshi goes in to this association in more detail and discusses the impact of exposure to, and persistence of, CAR T-cells along with the implications of the development of an anti-CAR T-cell immune response.